cyrilzakka/clinical-trials huggingface dataset:
Measuring Motor Imagery Ability in Patients With Traumatic Brain Injury.

1. Validation of translated Motor Imagery ability questionnaire MIQ-RS
2. Investigating the Motor Imagery ability in patients with traumatic brain injury

1. Translation of the MIQ-RS following the WHO guidelines. Followed by a validation of this translated questionnaire in patients with traumatic brain injury and in healthy volunteers.
2. Investigating the motor imagery ability using 3 different test

   * MIQ-RS (movement imagery questionnaire)
   * TDMI (time dependent motor imagery)
   * mental chronometry test

Patients and controls will perform all 3 test twice with an interval of 2 weeks to measure the test-retest reliability.

Eligibility Criteria:
Inclusion Criteria:

* TBI minimum 3 months ago and maximal 1 year ago

Exclusion Criteria:

* Other neurological disorders
* Severe cognitive deficits, unable to understand the study protocol
* Severe motor impairment, unable to perform the TDMI (Time Dependent Motor Imagery) screening test

Control group:

Matched for age, sex and educational level No neurological disorders present
Therapeutic Efficacy of Intense Pulsed Light in the Treatment of Chalazion

Study method: This test screened the subjects first, and proposed to include 50 subjects with primary or recurrent eyelid plate gland cysts without obvious surgical indications. All subjects underwent three strong pulsed light therapy combined with eyelid plate gland massage, treatment of local anesthesia eye drops, and metal pads were placed in conjunctival sac protection. Eye protection, using the M22 strong pulsed light small optical treatment head of the medical company, energy selection 14-16J/cm2, laser position is selected on the upper and lower eyelids, 3mm away from the root of the eyelashes. Each interval is 3 weeks. Eye-related examinations were performed before treatment and 3 times after treatment. The evaluation content included: ocular surface, slit lamp observation, anterior segment photography, intraocular pressure, vision, corneal fluorescein staining, tear film rupture time, eyelid plate gland evaluation, eyelid plate gland cyst relief, eyelid plate gland cyst recurrence rate.


Eligibility Criteria:
Inclusion Criteria:

* Patients had primary or recurrent eyelid plate gland cyst without obvious surgical indications

Exclusion Criteria:

* (1) any intraocular inflammation, ocular infection, allergy, ocular surgery, or ocular trauma in the past 6 months; (2) any eyelid diseases or structural abnormality; (3) any systematic diseases may lead to dry eye or MGD; (4) skin cancer or pigmented lesion in the treatment zone.
Comparison of High Flex and Standard Rotating Platform Total Knee Arthroplasty (TKA)

The goal of this study is to determine if the rotating platform high flex design provides improved flexion compared to the standard rotating platform TKA.


Eligibility Criteria:
Inclusion Criteria:

* Age 40 to 75 years old
* Primary diagnosis of osteoarthritis of the knee
* Patients who, in the investigator's opinion, are appropriate candidates for a cemented, rotating platform TKA.
* Patients who, in the investigator's opinion, are capable of participation in a clinical trial and reliable enough to return for follow-up appointments.

Exclusion Criteria:

* Pregnant or lactating female subjects
* Patients with post-traumatic or inflammatory arthritis
* Patients with a fixed flexion contracture of greater than 20 degrees
* Patients with advanced hip, spine, or ankle disease
* Patients with a BMI greater than 40, where knee flexion may be limited by soft tissues
Effectiveness of Endoscopic Papillectomy With Stent for Treating Duodenal Papillary Adenoma

This is a retrospective study, including 79 patients with duodenal papillary adenoma, who treated with Endoscopic Papillectomy (EP) at Beijing friendship hospital. The cohort included patients who underwent EP with or without Pancreatic Duct (PD) and Common Bile Duct (CBD) stent placement. The investigators assessed the outcomes of EP and the impact of stent placement on complications and recurrence rates.

Duodenal papillary adenoma, a potentially malignant benign tumor is primarily treated with endoscopic papillectomy. Despite its efficacy, endoscopic papillectomy has a high complication rate. This study investigates whether pancreatic duct and common bile duct stent placement can mitigate these complications. In a retrospective analysis, 79 patients with duodenal papillary adenoma, treated with endoscopic papillectomy at our center, were studied. The cohort included patients who underwent endoscopic papillectomy with no stents placement, common bile duct stent placement alone, pancreatic duct stent placement alone, or stents placement in both ducts. Complete resection rates did not significantly differ between patients with or without stent placement. Early complication rates were similar across groups. However, significant reduction in common bile duct stenosis was observed in the stenting group. Furthermore, stent placement correlated with lower adenoma recurrence rates during follow-up. Thus, Pancreatic duct and common bile duct stent placement in endoscopic papillectomy may decrease late complications, particularly common bile duct stenosis, and reduce the recurrence of duodenal papillary adenoma.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years.
* Identification of duodenal papillary lesions via gastroscopy or duodenoscopy.
* Intraductal involvement \<20mm.
* Absence of preoperative peripheral lymph node metastasis and pancreatic/biliary duct stenosis (verified by CT, MRI, or other imaging).
* Postoperative biopsy confirming adenoma.

Exclusion Criteria:

* Diagnosis of familial adenomatous polyposis or multiple hamartoma syndrome.
* Patients undergoing pancreaticoduodenectomy within a month post-EP for residual lesions.
Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®

The infection rate after Total Hip Arthroplasty (THA) is about 1%. It is a serious condition, with high morbidity, sometimes fatal, requiring costly treatment.

The treatment is difficult because "biofilm" forms very early after the bacterial contamination of the prosthesis.

Prevent infection means reduce or prevent the formation of bacterial biofilm and controlling protein response to allow osseous-integration of the prosthesis.

A new prosthesis was developped, grafted by PolyNaSS (polysodium styrenesulfonate). This bioactive polymer allows to substantially reduce bacterial adhesion, biocompatibility, bio-integration in preclinical studies. This first clinical study aims to compare the osseous-integration of this prosthesis to the same prothesis with no grafting.

No previous clinical trial


Eligibility Criteria:
Inclusion Criteria:

* THA following a primary or secondary osteoarthritis
* THA following an aseptic osteonecrosis
* Social insurance
* Informed and signed consent

Exclusion Criteria:

* Patients younger than 50 years and with joint lesions that can be successfully treated with conservative treatment
* Rheumatoid arthritis
* Steroid treatment on-going
* Tumor Pathology of the hip bone
* Loss of bone of the joint that makes it impossible to properly anchor a cementless prosthesis
* Acetabular or femoral bone graft associated
* Infectious hip arthritis history
* Evolving infection of the articulation or peri-articular region involved, including severe neuroarthropathy
* Surgical history on the affected hip
* Allergy known to any component of prostheses
* Known hypersensitivity to polystyrene sulfonate resins
* Native cotyl with a diameter of less than 42mm or greater than 68mm
* Significant muscle loss, neuromuscular injury or vascular insufficiency of affected limb
* Charcot's disease
* Immunocompromised patients
* Difficulties of follow-up (departure on vacation, imminent change, geographical distance, patients not residing in metropolis, insufficient motivation) or understanding of the protocol
* Patient Refusal
* Pregnant and lactating women
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.


Eligibility Criteria:
Key Inclusion Criteria:

* Individuals with the following histologically documented metastatic (M1, Stage IV) or locally advanced solid tumors

  * NSCLC (adenocarcinoma or SCC) that has progressed after prior platinum-based chemotherapy and programmed death-(ligand) 1 (PD-(L)1) directed therapy
  * HNSCC that has progressed after prior platinum-based chemotherapy and anti-PD-(L)1 directed therapy No more than 3 prior lines of systemic treatment is allowed
  * Endometrial carcinoma that has progressed after prior platinum-based chemotherapy and anti-PD-(L)1 directed therapy No more than 3 prior lines of systemic treatment is allowed.
  * Extensive stage SCLC that has progressed after prior platinum-based chemotherapy and PD-(L)1 directed therapy. No more than one prior line of systemic treatment is allowed (re-challenge with the same initial regimen is not allowed)
* Eastern Cooperative Oncology Group (ECOG) Performance status score of 0 or 1
* Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation
* Adequate hepatic and renal function (CrCl ≥30mL/min)
* Individual must have at least a 3-month life expectancy
* Have measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria

Key Exclusion Criteria:

* Have had a prior anti-cancer biologic agent within 4 weeks prior to study Day 1 or have had prior chemotherapy, targeted small molecule therapy, radiation therapy within 2 weeks prior to Study Day 1
* Have not recovered (i.e., ≤ Grade 1) from adverse events due to a previously administered agent
* Have previously received topoisomerase I inhibitors
* Have an active second malignancy
* Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Individuals with previously treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and all neurologic symptoms have returned to baseline, have no evidence of new or enlarging brain metastases and are taking ≤20 mg/day of prednisone or its equivalent. All individuals with carcinomatous meningitis are excluded regardless of clinical stability
* Additional cohort specific exclusion criteria

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Using Urine Samples to Identify Lung Cancer

The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC.

The ABP test uses laboratory animals that are trained to detect (by smell) different chemicals in urine. Studies show that people with lung cancer have unique chemicals in their urine that are not present in people without lung cancer, and researchers think these chemicals can be used to identify people with lung cancer without the need for invasive procedures (like biopsy).


Eligibility Criteria:
Inclusion Criteria:

* Phase I (with NSCLC): Aged 18 to 90 years with histologically proven, previously untreated stage I, II, or IIIA NSCLC

  °Note: Single, monolateral nodule of at least 50% solid composition visible on a Chest CT scan that is suspicious for a primary neoplasm as confirmed by an official MSK radiologist read
* Phase I (without NSCLC): Aged 18 to 90 years with patient confirmed absence of NSCLC
* Phase II: Aged 18 to 90 years with suspected but undiagnosed stage I, II, or IIIA NSCLC by CT and/or PET scan criteria

Exclusion Criteria:

* Aged \<18 years
* Lack of available results from low-dose CT
* Receipt of radiation, chemotherapy, biological therapy, resection, or any other treatment for any cancer in the previous year
* Pregnant (for women)
* Taking drugs that affect the immune system
* Chronic disease related to the immune system
* Missing clinical data (i.e., current clinical staging)
Casptesia Versus PICCO in Cardiac Surgical Patients in the ICU

The goal of this study is to assess the ability of a new smartphone PPV app to predict fluid responsiveness in cardiac surgical patients in the Intensive care unit (in the postoperative period)

Pulse pressure variation (PPV) remains a good predictor of fluid responsiveness in the ICU in ventilated and sedated patients. However, PPV can be time-consuming to calculate (manual determination), is not always displayed on monitoring screens nor reliable through visual assessment and needs additional often costly devices to be displayed. A new Android application (Captesia) automatically calculates the PPV utilizing a digital photograph of the arterial waveform from the monitor. The application determines the PPV by selecting peaks and troughs of the arterial curve.

Eligibility Criteria:
Inclusion Criteria:

* adults patients ( \>18 years)
* Patients scheduled for cardiac surgery
* equipped with a femoral arterial catheter and the PICCO device

Exclusion Criteria:

* Atrial fibrillation
* severe cardiac dysfunction
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

This study will examine specific biomarkers in primary invasive breast cancer and explore their correlation with patient outcome following standard neoadjuvant treatment.


Eligibility Criteria:
Inclusion Criteria:

* The patient has 18 years of age or older at the time of consent.
* The patient has provided pre-treatment tumor samples for WT1 expression screening and gene expression profiling in the context of the NCT01220128 study.
* The patient has a histologically or cytologically confirmed primary invasive breast cancer.
* The patient has provided written informed consent before any new information or new material is provided to the Sponsor.
* The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.
* The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.

Exclusion Criteria:

Not applicable.
MeasurIng and Restoring Auditory Awareness for Cochlear Implant Listeners in noisE

The goal of this interventional study is to describe how people with cochlear implants perceive the perceive speech in noise and their sound environment on adults who are native French speakers with typical hearing or with cochlear implant(s).

The measures and strategies developed in this project could benefit all current and future cochlear implant wearers by improving their perception of the sound environment and their quality of life on a daily basis.

Researchers will compare normal hearing participant and participants with cochlear implant to describe the speech in noise and their perception of the sound environment.

Participants will perform audiological tests to assess their perception of the sound environment, with and without speech enhancement.


Eligibility Criteria:
Inclusion Criteria:

For all participants:

* 18 years of age or over,
* Native French speaker,
* Having given their consent to take part in the research.

For cochlear implant patients:

* Adult implanted and declaring that they have been using the implant for at least 18 months,
* Normal speech audiometry in silence

For controls reporting normal hearing:

* Normal tonal audiometry (defined as a mean tonal loss not exceeding 30 decibel (dB) HL)
* Normal speech audiometry in noise (SNR between -8 dB and -4dB inclusive)

Exclusion Criteria:

* Be under guardianship or curatorship,
* deprived of liberty by judicial or administrative decision, or subject to legal protection,
* Non- native French speaker.
Influence of Paternal Age on Assisted Reproduction Outcome

In the recent years, there is an increasing tendency to the parenthood delay in developed countries, and there is not enough information available regarding the influence of the male's age on fertility. If any, the negative impact should be acting at advanced ages.

Our aim with this work was to determine the role of paternal age on IUI results embryo quality and IVF outcome. Evenmore, in order to standardize the female factor, good quality oocytes (from fertile oocyte donors) and only first IVF cycles in young women were considered.

A retrospective study has been designed with a total number of 2204 IUI, 1286 IVF cycles and 1412 IVF cycles with donated oocytes from 2000 to 2006.

The inclusion criteria will be for IUI: women under 38 years old, tubal patency demonstrated by hysterosalpingography, normal uterine scan, normal basal hormonal levels, body mass index \< 27 kg/m2, and absence of polycystic ovarian syndrome and endometriosis. For normal IVF cycles and oocyte donation cycles only first cycles will be analyzed. Cycles will be studied only in couples with absence of severe male factor.

Eligibility Criteria:
Inclusion Criteria:

* women under 38 years old, tubal patency demonstrated by hysterosalpingography, normal uterine scan, normal basal hormonal levels, body mass index \< 27 kg/m2.

Exclusion Criteria:

* absence of polycystic ovarian syndrome, hydrosalpinx or endometriosis.
* Cycles were studied only in couples with absence of severe male factor.
National Observatory of Children Hospitalized for Bronchiolitis

This study is an observational, multicenter and prospective study for surveillance of case of hospitalised children for bronchiolitis associated or not to RSV or other viruses (isolated or associated with RSV)

The aim of this surveillance is to observe and describe the cases hospitalized for bronchiolitis in the 2023/2024 season in the context of routine immunization with Nirsevimab.

Eligibility Criteria:
Inclusion Criteria:

* Children under 12 months of age
* In one of the 6 study sites
* From October 15, 2023
* For acute bronchiolitis defined according to current national and international recommendations
* Hospitalized from the pediatric emergency department.

Exclusion Criteria:

- Refusal to participate by patient relative or legal representative
ChemoFx® PRO - A Post-Market Data Collection Study

This study will collect patient demographic, oncology history, and physician reported outcome information following the initial round of chemotherapy received after a commercial ChemoFx® Final Report for the generation of hypotheses of potential patient cohorts for further sub-studies.

The traditional treatment course for new cases of many cancers is cytoreductive surgery followed by chemotherapy. Unfortunately, despite high initial response rates to treatment, the majority of patients recur. The use of ineffective chemotherapy can result in unnecessary toxicity and costs, delay of more effective treatment, and the potential for the development of cross-resistance to additional drugs. The ability to individualize therapy by providing the treating physician with ex vivo response information on a panel of drugs should aid in the selection of effective therapy for individual patients, thus resulting in improved outcomes.

ChemoFx® is a drug response marker that quantifies an individual cancer patient's probable tumor response to various chemotherapeutic and biologic agents-providing both sensitivity and resistance information. In a retrospective study, it was demonstrated that patients treated with a regimen that the ChemoFx® test said the patients' cells would be sensitive to, corresponded to a 3 times longer progression free interval.

In the PT-206 ChemoFx PRO® study, patients will be followed through treatment, until the patient progresses or a significant change in chemotherapy occurs. This data will be collected and analyzed to identify potential patient cohorts for the development of hypotheses for future sub-study analysis. Also, tumor pathology slides and excess tumor cells (if available) will be used to characterize common polymorphisms in drug metabolizing enzymes as well as other molecular markers potentially associated with tumor response.

The PT-206 ChemoFx PRO® Study seeks to enroll an estimated 3,000 patients from 150 academic and community-based physicians in the U.S. The patients will be treated with drugs and/or drug combinations based on the medical judgment of the treating physician. This study is not randomized.

Eligibility Criteria:
Inclusion Criteria:

* Patient has been diagnosed with a solid tumor malignancy and their physician has received a final report for ChemoFx® after August 1, 2006
* Chemotherapy must be clinically indicated for treatment of the patient's qualifying disease
* Patient must be at least 18 years of age
* Patient must have signed an IRB approved informed consent form for the data collection study prior to entry of data into the enrollment form in the database.

Exclusion Criteria:

* Patient pathology shows benign pathology for sample submitted
* Patient is not indicated to receive chemotherapy for their disease
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in adolescent outpatients (12-17) with major depressive disorder.


Eligibility Criteria:
Inclusion Criteria:

* Male or Female outpatients between 12-17 years of age
* Primary diagnosis of major depressive disorder (MDD)
* Children's Depression Rating Scale-Revised (CDRS-R) score of 40 or greater
* Clinical Global Impressions-Severity (CGI-S) score of 4 or greater

Exclusion Criteria:

* Current (past 3 months) principal Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) based diagnosis of an axis disorder other than major depressive disorder (MDD) that is the primary focus of treatment.
* History of suicidal behavior, or requires precaution against suicide
* Not generally healthy medical condition
* Seizure disorder